Microbiological mechanisms of immune response modulation: clinical implications

Abstract

The human microbiota is a major regulator of immune development, mucosal barrier integrity, and systemic immune tone. Its effects are mediated by microbe-associated molecular patterns, pattern-recognition receptors, microbial metabolites such as short-chain fatty acids, tryptophan-derived indoles, secondary bile acids and vitamin-pathway metabolites, and direct interactions with epithelial and immune cells. A balanced microbiota supports regulatory T-cell responses, secretory IgA production, innate-like lymphocyte maturation and epithelial barrier function, whereas dysbiosis may promote barrier dysfunction, inflammatory polarization and abnormal responses to dietary, environmental or self-antigens. This narrative review integrates mechanistic and translational evidence across early-life immune maturation, innate and adaptive immune sensing, microbial metabolites, cross-kingdom interactions, gut-organ axes, immune-mediated diseases and microbiota-targeted interventions. Particular emphasis is placed on distinguishing mechanistic evidence from association. Although microbiome-directed therapies are promising, routine clinical translation requires standardized sampling and multi-omics workflows, controlled interventional studies, mechanistic validation, reproducible biomarkers and indication-specific evidence.